Browsing by Author "Bolukbasi, Y"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Evaluation of anxiety level during intracavitary brachytherapy applications in patients with gynecologic malignancy
    Yalman, D; Kamer, S; Ozsaran, Z; Celik, O; Bolukbasi, Y; Bildilk, O; Haydaroglu, A
  • No Thumbnail Available
    Item
    POSTOPERATIVE RADIOTHERAPY IN THE MANAGEMENT OF RESECTED NON-SMALL-CELL LUNG CARCINOMA: 10 YEARS' EXPERIENCE IN A SINGLE INSTITUTE
    Karakoyun-Celik, O; Yalman, D; Bolukbasi, Y; Cakan, A; Cok, G; Ozkok, S
    Purpose: This study reports the long term outcomes of postoperative radiotherapy in patients with resection for non-small-cell lung cancer (NSCLC). Methods and Materials: A total of 98 patients with resected NSCLC who received postoperative radiotherapy (PORT) between January 1994 and December 2004 were retrospectively analyzed. The most frequently performed surgical procedure was lobectomy (59 patients), followed by pneumonectomy (25), wedge resection (8), and bilobectomy (6). Postoperative radiotherapy was delivered as an adjuvant treatment in 71 patients, after a wedge resection in 8 patients, and after an R1 resection in 19 patients. The PORT was administered using a Co-60 source in 86 patients and 6-MV photons in 12 patients. A Kaplan-Meier estimate of overall survival, locoregional control, and distant metastasis-free survival were calculated. Results: Stages included I (n = 13), II (n = 50), IIIA (n = 29), and IIIB (n = 6). After a median follow-up of 52 months median survival was 61 months. The 5-year overall survival, locoregional control, and distant metastasis-free survival rates for the whole group were 50%, 78%, and 55% respectively. The RT dose, Karnofsky performance status, age, lateralization of the tumor, and pneumonectomy were independent prognostic factors for OAS; anemia and the number of involved lymph nodes were independent prognostic factors for LC. Conclusions: Doses of PORT of greater than 54 Gy were associated with higher death rate in patients with left-sided tumor, which may indicate a risk of radiation-induced cardiac mortality. (C) 2010 Elsevier Inc.
  • No Thumbnail Available
    Item
    High dose rate endobronchial brachytherapy in the management of lung cancer: Response and toxicity evaluation in 158 patients
    Ozkok, S; Karakoyun-Celik, O; Goksel, T; Mogulkoc, N; Yalman, D; Gok, G; Bolukbasi, Y
    The aim of this study was to evaluate the symptomatic and endoscopic responses as well as the toxicities in 158 patients with endobronchial. lung cancer treated with high dose rate endobronchial. brachytherapy (HDR-EB). Forty-three patients with stage III NSCLC were treated with 60 Gy external beam radiotherapy (ERT) and three applications of 5 Gy each of HDR-EB (group A). Seventy-four patients who did not receive previous RT were treated with 30Gy ERT and two applications of 7.5 Gy HDR-EB with palliative intent (group B). Forty-one patients with recurrent tumor who were irradiated previously were treated with three applications of 7.5 Gy HDR-EB, with palliative intent (group C). In group A, bronchoscopic complete (CR) and overall response rates (ORR) were 67% and 86%, respectively. Symptomatic improvement was obtained in 58% of patients with cough, 77% of patients with dyspnea and 100% of patients with hemoptysis. Two and 5-year survival rates were 25.5% and 9.5%, respectively and the median survival time (MST) was 11 months. In group B, the bronchoscopic CR and ORR were 39% and 77%, respectively and 28% and 72% in group C. The symptomatic response rates were 57% and 55% for cough, 90% and 78% for dyspnea and 94% and 77% for hemoptysis, with a MST of 7 and 6 months in Groups B and C, respectively. Eighteen patients (11%) died of fatal hemoptysis (FH) with the median time to this event of 7 months. Treatment intent (p < 0.001), totat BED (p < 0.001) and the number of HDR-EB fractions (p < 0.001) were significant prognostic factors for FH. HDR-EB provides effective palliation in relieving the symptoms of patients with enclobronchial lung cancer, however, there is a risk of developing FH that is associated with a high BED and multiple HDR-EB applications. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
  • No Thumbnail Available
    Item
  • No Thumbnail Available
    Item
    The Treatment Outcomes of Oligometastatic Colorectal Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Multi-Institutional Analysis TROD 02-008
    Guler, OC; Hurmuz, P; Atalar, B; Guney, YY; Saglam, EK; Akyurek, S; Bolukbasi, Y; Güral, Z; Tugrul, F; Korcum, AF; Sen, CA; Yildirim, BA; Oksuz, DC; Celik, OK; Kurt, M; Guzeloz, Z; Yavas, G; Ozyigit, G; Aksu, MG; Onal, C